GLPG1205: Clinical Trials

6 trials of GLPG1205, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed. 6 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 16Completed 6

Follow GLPG1205: new trials by email Literature Review of GLPG1205 trials Research Report on GLPG1205

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205
GLPG1205 film-coated tablets, [14C]-GLPG1205 solution for infusion, GLPG1205 capsules - Healthy
Phase 1CompletedLakefront Biotherapeutics NV122021-01-132021-03-25
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects
GLPG1205, Placebo - Healthy
Phase 1CompletedLakefront Biotherapeutics NV322020-08-182020-12-22
This is a Study to Evaluate the Effect of Aging of Multiple Doses of GLPG1205 in Healthy Subjects
GLPG1205 50mg q.d., Placebo oral capsule, GLPG1205 250 loading dose and 50mg q.d. maintenance dose - Healthy, Elderly
Phase 1CompletedLakefront Biotherapeutics NV322016-10-182017-04-05
A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male Subjects
GLPG1205, Placebo, Cocktail of CYP450 substrates - Healthy
Phase 1CompletedLakefront Biotherapeutics NV142015-10-012016-02-23
Oral Bioavailability of Solid Formulation of GLPG1205 With and Without Food
100 mg GLPG1205 - Healthy
Phase 1CompletedLakefront Biotherapeutics NV122014-05-012014-07-22
First-in-Human Single and Multiple Dose of GLPG1205
GLPG1205 single ascending doses, oral suspension, Placebo single ascending doses, oral suspension, GLPG1205, multiple ascending doses, oral suspension - Healthy
Phase 1CompletedLakefront Biotherapeutics NV402013-06-012013-10-16

Sponsors

Lakefront Biotherapeutics NV (6)

Countries

Belgium (4)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Ekaterina Tankisheva, MD (1)  ·  Ekaterina Tankisheva, MD, PhD (1)  ·  Helen Timis, MBChB MICR (1)

Results publications

PMID 33955686

NIH funding

2015 (1)